" class="no-js "lang="en-US"> Cordio Medical - Medtech Alert
Monday, October 07, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Cordio Medical | Pharmtech Focus

Cordio Medical

About Cordio Medical

Cordio Medical
Cordio develops and provides groundbreaking solutions for monitoring health conditions through a patient’s voice. A patient’s free speech into a smartphone app backed by sophisticated and proprietary algorithms, allows near real-time monitoring and early detection of condition deterioration. Cordio technologies are based on true speech signal processing technology, unique to each patient, augmented with machine learning capabilities. The system is patient-tailored, and is constantly learning the patient’s voice and providing personalized, seamless and effortless monitoring. Cordio’s goal is to identify and mitigate condition worsening by helping physicians prevent patient deterioration and hospitalization while keeping the patient

Related Story

Fundraising

 Cordio Medical Raises $18 Million in Funding From Ceros and Peregrine Ventures to Accelerate Growth | Pharmtech Focus

Cordio Medical Raises $18 Million in Funding From Ceros and Peregrine Ventures to Accelerate Growth

June 28 2022

Cordio Medical, a market-leading medical speech processing platform, announced its latest successful strategic investment round […]